RedHill Biopharma reported $18.38M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Cara Therapeutics USD 39.02M 4.73M Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
Cronos Group USD 1.2B 18.73M Dec/2025
RedHill Biopharma USD 18.38M 332K Jun/2025